...
首页> 外文期刊>Current medicinal chemistry >Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
【24h】

Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents

机译:间充质干细胞在黑素瘤中的应用:潜在的靶向药物治疗策略。

获取原文
获取原文并翻译 | 示例
           

摘要

Melanoma is a leading cause of mortality from skin cancer and has a poor prognosis. Despite rapid advances in the treatment of this tumor type, the efficacy of current chemo-/targeted-therapies is still limited owing to the lack of sufficient drug accumulation in the tumor tissue and development of chemo-resistance. Recently, the application of mesenchymal stem cells (MSCs) in cancer therapy has gained substantial attention, suggesting their potential roles as an intriguing vehicle in improving the delivery of targeted agents. MSCs are genetically modified with suicide tumor suppressor genes to inhibit cell signaling pathways associated with the progression and metastatic features of melanoma. Here we describe the clinical application of MSCs in melanoma with a particular emphasis on recent findings on the role of MSC expressing a distinct set of biologically functional chemokines and tumor suppressing agents. Accumulating data has shown the tumor-oriented homing capacity of MSCs and their applications as a vehicle (e.g., adipose derived mesenchymal stem cells expressing TRAIL, interferon-alpha/gamma, pigment epithelium-derived factor and cytosine deaminase). Several questions regarding possible potential and intrinsic mechanisms that might induce tumorigenesis and drug resistance are yet to be addressed for tailoring MSC-nbased treatment of melanoma.
机译:黑色素瘤是导致皮肤癌死亡的主要原因,并且预后不良。尽管在这种肿瘤类型的治疗方面取得了快速的进展,但是由于在肿瘤组织中缺乏足够的药物积累和抗化学性的发展,目前的化学/靶向疗法的疗效仍然受到限制。最近,间充质干细胞(MSCs)在癌症治疗中的应用受到了广泛关注,表明它们在改善靶向药物的输送中作为令人感兴趣的媒介物的潜在作用。 MSC用自杀性肿瘤抑制基因进行了基因修饰,以抑制与黑色素瘤的进展和转移特征相关的细胞信号通路。在这里,我们描述了MSC在黑色素瘤中的临床应用,特别强调了关于MSC表达不同生物学功能趋化因子和肿瘤抑制剂的作用的最新发现。越来越多的数据表明,MSCs的肿瘤定向归巢能力及其作为媒介物的应用(例如,脂肪表达的间充质干细胞表达TRAIL,干扰素-α/γ,色素上皮衍生因子和胞嘧啶脱氨酶)。关于可能基于肿瘤的潜在机制和内在机制可能引发肿瘤发生和耐药性的几个问题,尚待解决,以量身定制基于MSC-n的黑色素瘤治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号